Sona Nanotech, Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. has announced promising results in a murine breast cancer study, where its combined targeted hyperthermia therapy and interleukin-2 treatment led to systemic immune responses and tumor shrinkage, including in untreated tumors. This rare abscopal effect indicates potential for enduring cancer treatment benefits. The company is moving towards additional studies and regulatory steps for potential human trials.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
